SAN DIEGO, May 14 /PRNewswire/ -- PacificGMP, the leader in utilizing
single-use bioprocessing for development and manufacturing for its client
partners, announced today that it has completed a product fill under GMP
(good manufacturing practices) standards for a Trius Therapeutics Phase I
"We are pleased to have worked closely with Trius on this GMP fill
project, an effort that we were able to initiate quickly and complete
within a narrow deadline," said Leigh N. Pierce, president of PacificGMP.
"Although our client base consists of mainly biologics drug developers,
PacificGMP has completed projects for a variety of other customers
including small molecule drug developers like Trius, as well as academic
institutions and diagnostics companies."
"PacificGMP successfully completed our GMP product fill and I
appreciated their flexibility and willingness to work with us to get the
job done in a timely and professional manner," said Jeffrey Barker,
Director of Pharmaceutical Development for Trius Therapeutics.
PacificGMP is a contract manufacturing organization (CMO) and industry
leader in utilizing single-use bioprocessing for development and
manufacturing of biologics. Single-use technology eliminates the risk of
cross-contamination, has fewer system requirements and significantly
reduces the time required to initiate production. Benefits to clients
include rapid project turnaround and the most cost effective solution in
the industry. PacificGMP provides cGMP and non-GMP services ranging from
cell line optimization, early process design, development and scale-up, to
preclinical and clinical biologics manufacturing, purification and
fill/finish. More information can be found by visiting the Company's web
site at http://www.pacificGMP.com.
About Trius Therapeutics
Trius Therapeutics is discovering and developing innovative
antibacterial drugs for the treatment of infections caused by resistant
pathogens. The company's lead drug candidate, TR-701 is a novel, oral and
IV, oxazolidinone antibiotic with potent activity against drug-resistant
Gram-positive bacterial pathogens including those resistant to Zyvox(R).
Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A
Pharmaceuticals. Trius' pipeline includes two additional structure-based
drug design programs directed against novel antibacterial targets. For more
information, visit http://www.triusrx.com.
Available Topic Expert(s): For information on the listed expert(s), click
Chief Business Officer